Applied Therapeutics, Inc. (APLT)
After hours:
| Previous Close | 4.2300 |
| Open | 4.2500 |
| Bid | 4.2500 x 100 |
| Ask | 4.3100 x 200 |
| Day's Range | 4.2400 - 4.4500 |
| 52 Week Range | 1.1800 - 9.3900 |
| Volume | |
| Avg. Volume | 1,831,817 |
| Market Cap | 488.956M |
| Beta (5Y Monthly) | 1.81 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.4200 |
| Earnings Date | May 09, 2024 - May 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.60 |
GlobeNewswireApplied Therapeutics Appoints Dale Hooks as Chief Commercial Officer
NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced the appointment of Dale Hooks as Chief Commercial Officer, replacing Adam Hansard, effective immediately. Mr. Hooks joins Applied with over 30 years of biopharmaceutical experience in rare disease marketing and sales, holding v
- GlobeNewswire
Applied Therapeutics to Present Results from Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at ACC 2024
NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will present full results from the Phase 3 ARISE-HF study evaluating AT-001 (caficrestat) in Diabetic Cardiomyopathy (DbCM) in an oral presentation at the 2024 American College of Cardiology (ACC) Annual Scientific Sess
- Reuters
UPDATE 1-US FDA extends review of Applied Therapeutics' genetic disease drug
The U.S. Food and Drug Administration has extended its review of Applied Therapeutics' experimental drug to treat galactosemia, a rare genetic metabolic disease, the company said on Thursday. There are currently no approved treatments for the disease in the United States, which has about 3,000 Galactosemia patients. The FDA delayed its decision on the drug, govorestat, saying it requires additional time to review supplemental analyses submitted by the company.
